title: Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro.
abstract: The effects of 2-lysophosphatidylcholine (2-LPC), the alkyl lysophospholipid derivatives (ALP) 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) and 1-O-hexadecyl-sn-glycero-3-phospho-trimethyl-ammonio-hexanol, the 2-acetamide analog of platelet-activating factor (PAF) 1-O-octadecyl-2-acetamide-sn-glycero-3-phosphocholine, the thioether lysophospholipid derivative (TLP) BM 41.440 and the ether-linked lipoidal amine CP-46,665 on tritiated thymidine uptake and trypan blue dye exclusion were tested in vitro in various freshly explanted cell samples from human nonneoplastic bone marrow and human leukemias. In both assay systems, a dose range of 1-20 micrograms/ml of the compounds was tested after 24, 48 and 72 hr of coincubation with the cells. The trypan blue dye exclusion revealed statistically significant preferential cytotoxicity in leukemic cells for three compounds with the order of quantitative selectiveness: ET-18-OCH3 greater than BM41.440 greater than 2-acetamide analog of PAF. CP-46,665 was the most toxic compound, but did not reveal significant differences between nonneoplastic bone marrow and leukemic cells when added in concentrations greater than 1 microgram/ml. The trimethyl-ammonio-hexanol compound showed only minor activity in the majority of tests, when added at concentrations less than 20 micrograms/ml. 2-LPC was rather ineffective. The tritiated thymidine uptake showed only preferential antiproliferative effects towards leukemic cells of ET-18-OCH3 and, sometimes, within the dose time frame tested of BM 41.440. All compounds tested except 2-LPC and the trimethyl-ammonio-hexanol compound were active also in this assay (inhibition of uptake greater than 50% of the controls).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine I, Technische Universitaet, Munich; Federal Republic of Germany.
authors.forename: H D
authors.initials: HD
authors.lastname: Schick
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
authors.forename: M
authors.initials: M
authors.lastname: Fromm
authors.forename: U
authors.initials: U
authors.lastname: Fink
authors.forename: U
authors.initials: U
authors.lastname: Jehn
authors.forename: K
authors.initials: K
authors.lastname: Ulm
authors.forename: A
authors.initials: A
authors.lastname: Reichert
authors.forename: H
authors.initials: H
authors.lastname: Eibl
authors.forename: C
authors.initials: C
authors.lastname: Unger
authors.forename: J
authors.initials: J
authors.lastname: Rastetter
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects*; D001854:Bone Marrow Cells; D002470:Cell Survival / Q000187:drug effects; D003603:Cytotoxins / Q000494:pharmacology*; D006801:Humans; D007938:Leukemia; D010755:Organophosphates / Q000494:pharmacology; D010742:Phospholipid Ethers / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000031:analogs & derivatives; D013936:Thymidine; D014407:Tumor Cells, Cultured / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D003603:Cytotoxins; D010755:Organophosphates; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; C026659:edelfosine; C043297:ilmofosine; D013936:Thymidine